pharmaceutical-investing Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
OHA is Joint Lead Arranger for Private Unitranche Financing Supporting Berkshire's Acquisition of United Flow Technologies